Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 852 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention-Deficit Hyperactivity Disorder Clear all
Completed Phase 2 Interventional

Open-Label, Extension Study to 810P202

NCT01416064
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD in Children
Interventions
Molindone
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Jul 23, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Vyvanse, fMRI, Placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional

Reminder Focused Positive Psychiatry in Adolescents With ADHD and PTSD

NCT04336072
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
RFPP, TFCBT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
9 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02225106
View directory record Official record
Conditions
Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

NCT02618434
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Little Rock, Arkansas • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Results available

Software Treatment for Actively Reducing Severity of ADHD

NCT02674633
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
AKL-T01, AKL-T09
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Dothan, Alabama • Scottsdale, Arizona • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Jul 23, 2026, 6:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Target ADHD Executive Working Memory Replication Study

NCT06446284
View directory record Official record
Conditions
ADHD
Interventions
EWM Training, Placebo Training
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT02604407
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01238822
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

NCT05721235
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
4 Years to 5 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Centennial, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01462032
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Training Executive, Attention and Motor Skills (TEAMS), Parent support and education
Behavioral
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
48 Months to 71 Months
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2 Interventional

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD

NCT02884544
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
HLD100
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults

NCT01853280
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-methylfolate, OROS-Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 23, 2026, 6:17 PM EDT
Completed No phase listed Observational Results available

Refining the Shared Decision Making Process Survey in ADHD Medication Decisions

NCT05048186
View directory record Official record
Conditions
ADHD
Interventions
Attention Deficit Hyperactivity Disorder Treatment Decision Aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 23, 2026, 6:17 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

An Investigational Study Examining the Cross-Validation of QbMobile in ADHD and Normative Populations

NCT07220330
View directory record Official record
Conditions
No History of ADHD, Attention Deficit Hyperactivity Disorder (ADHD), Healthy Volunteer
Interventions
QbMobile
Device
Lead sponsor
Qbtech AB
Industry
Eligibility
6 Years to 60 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Jose, California • Largo, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 6:17 PM EDT
Completed No phase listed Observational

Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

NCT01014195
View directory record Official record
Conditions
Neurocognitive Impairment, Acute Lymphoblastic Leukemia
Interventions
Neurocognitive and behavioral evaluation
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional

Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)

NCT00018863
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
3 Years to 5 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jul 23, 2026, 6:17 PM EDT
Not listed No phase listed Observational

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

NCT05751525
View directory record Official record
Conditions
Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy
Interventions
Sulfonylurea
Drug
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust
Other
Eligibility
2 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ventral Tegmental Area (VTA) Self-Activation in Attention Deficit Hyperactivity Disorder (ADHD)

NCT02723708
View directory record Official record
Conditions
ADHD
Interventions
Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04143217
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 23, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

NCT02048241
View directory record Official record
Conditions
Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
Interventions
Parent Management Training, Placebo, Intuniv
Behavioral · Other · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 23, 2026, 6:17 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

NCT00001246
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 120 Years
Enrollment
4,274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1990
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 6:17 PM EDT